Imperial College London

DrSalvatoreSantamaria

Faculty of MedicineDepartment of Immunology and Inflammation

Honorary Lecturer
 
 
 
//

Contact

 

s.santamaria

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

84 results found

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, TABLE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Primers for qRT-PCR. Primer sequences for VCAN isoforms and housekeeping gene RPS13&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 3 describes the transwell model&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 8 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 8 summarises the results identified.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 7 shows representative images of each phenotype&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate., Cancer Res Commun, Vol: 4, Pages: 970-985

UNLABELLED: Immunotherapies for cancers of epithelial origin have limited efficacy, and a growing body of evidence links the composition of extracellular matrix (ECM) with the likelihood of a favorable response to treatment. The ECM may be considered an immunologic barrier, restricting the localization of cytotoxic immune cells to stromal areas and inhibiting their contact with tumor cells. Identifying ECM components of this immunologic barrier could provide targets that whether degraded in situ may support antitumor immunity and improve immunotherapy response. Using a library of primary triple-negative breast cancer tissues, we correlated CD8+ T-cell tumor contact with ECM composition and identified a proteoglycan, versican (VCAN), as a putative member of the immunologic barrier. Our analysis reveals that CD8+ T-cell contact with tumor associates with the location of VCAN expression, the specific glycovariant of VCAN [defined through the pattern of posttranslational attachments of glycosaminoglycans (GAG)], and the cell types that produce the variant. In functional studies, the isomers of chondroitin sulfate presented on VCAN have opposing roles being either supportive or inhibiting of T-cell trafficking, and removal of the GAGs ameliorates these effects on T-cell trafficking. Overall, we conclude that VCAN can either support or inhibit T-cell trafficking within the tumor microenvironment depending on the pattern of GAGs present, and that VCAN is a major component of the ECM immunologic barrier that defines the type of response to immunotherapy. SIGNIFICANCE: The response to immunotherapy has been poor toward solid tumors despite immune cells infiltrating into the tumor. The ECM has been associated with impacting T-cell infiltration toward the tumor and in this article we have identified VCAN and its structural modification, chondroitin sulfate as having a key role in T-cell invasion.

Journal article

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 1 shows how VCAN was enriched and mass spectrometry analysis of the sample&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 5 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 5 outlines the analysis of matrix proteins in TMAs.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 6 shows VCAN analysis in the TIPs from the second tissue subset&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Effect of CS toward T-cell invasion. &lt;b&gt;A,&lt;/b&gt; CS MS completed on the crude and enriched protein from HMF3S and HCC38 cell lines. CS isomers and A/C ratio determined. &lt;b&gt;B,&lt;/b&gt; Transwell assay completed with 5 µg of each protein sample. Each sample was treated with ChABC for comparison. Heat map shows level of T cells invaded over time for one T-cell donor. Graphs show the level of migrated cells for HMF3S (&lt;b&gt;C&lt;/b&gt;) and HCC38 (&lt;b&gt;D&lt;/b&gt;) with error bars showing replicates with different T-cell donors.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Data from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;div&gt;Abstract&lt;p&gt;Immunotherapies for cancers of epithelial origin have limited efficacy, and a growing body of evidence links the composition of extracellular matrix (ECM) with the likelihood of a favorable response to treatment. The ECM may be considered an immunologic barrier, restricting the localization of cytotoxic immune cells to stromal areas and inhibiting their contact with tumor cells. Identifying ECM components of this immunologic barrier could provide targets that whether degraded &lt;i&gt;in situ&lt;/i&gt; may support antitumor immunity and improve immunotherapy response. Using a library of primary triple-negative breast cancer tissues, we correlated CD8&lt;sup&gt;+&lt;/sup&gt; T-cell tumor contact with ECM composition and identified a proteoglycan, versican (VCAN), as a putative member of the immunologic barrier. Our analysis reveals that CD8&lt;sup&gt;+&lt;/sup&gt; T-cell contact with tumor associates with the location of VCAN expression, the specific glycovariant of VCAN [defined through the pattern of posttranslational attachments of glycosaminoglycans (GAG)], and the cell types that produce the variant. In functional studies, the isomers of chondroitin sulfate presented on VCAN have opposing roles being either supportive or inhibiting of T-cell trafficking, and removal of the GAGs ameliorates these effects on T-cell trafficking. Overall, we conclude that VCAN can either support or inhibit T-cell trafficking within the tumor microenvironment depending on the pattern of GAGs present, and that VCAN is a major component of the ECM immunologic barrier that defines the type of response to immunotherapy.&lt;/p&gt;Significance:&lt;p&gt;The response to immunotherapy has been poor toward solid tumors despite immune cells infiltrating into the tumor. The ECM has been associated with impacting T-cell infiltration toward the tumor and in this article we have

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 4 shows different method of TIP analysis and the TIPs from different subsets of tissues.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 8 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 8 summarises the results identified.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 4 shows different method of TIP analysis and the TIPs from different subsets of tissues.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;CS isomers expression in tissues. &lt;b&gt;A,&lt;/b&gt; Structure of CS isoforms following digestion of the chains with ChABC. CS extracted from FFPE tissues in the epithelial zone and stromal zone. CS isoforms analyzed by MS to identify proportion of each isomer. &lt;b&gt;B,&lt;/b&gt; Comparison of isoforms in excluded and inflamed tissues within the different zones. Two-way ANOVA. &lt;b&gt;C,&lt;/b&gt; Comparison of isomer in the different zones within excluded and inflamed tissues. Two-way ANOVA. &lt;b&gt;D,&lt;/b&gt; CS-A/C ratio determined for the different regions of each phenotype and compared. ANOVA. &lt;b&gt;E,&lt;/b&gt; Level of sulfation per CS disaccharide in the different regions of each phenotype compared. *, &lt;i&gt;P&lt;/i&gt; &lt; 0.05; **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01; ****, &lt;i&gt;P&lt;/i&gt; &lt; 0.001.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;VCAN is associated with T-cell localization. &lt;b&gt;A,&lt;/b&gt; Matrix index from Pearce and colleagues (&lt;a href="#bib14" target="_blank"&gt;14&lt;/a&gt;). Arrows indicate upregulation or downregulation at gene (G) or protein (P) level. &lt;b&gt;B,&lt;/b&gt; Level of gene expression of top five upregulated molecules in 100 samples from TCGA dataset. &lt;b&gt;C,&lt;/b&gt; scRNA-seq expression of the five genes indicating which cell types express the genes and the percentage of those cells that are positive. Data obtained from Wu and colleagues (&lt;a href="#bib25" target="_blank"&gt;25&lt;/a&gt;). &lt;b&gt;D,&lt;/b&gt; IHC completed on consecutive TMA cores for COL11A1, COMP, CTSB, FN1, and VCAN. Spearman rank correlation of the expression of proteins from IHC analysis of eight TMA cores. **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01 (&lt;i&gt;N&lt;/i&gt; = 8). &lt;b&gt;E&lt;/b&gt;, Comparison of dual RNAscope for CTSB (green) and VCAN (red) with IHC staining for CD8.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Determining the immune phenotype of tumor tissues. A total of 26 TNBC tissues were analyzed for the TIP. &lt;b&gt;A,&lt;/b&gt; Annotation of slide on QuPath for analysis of the four regions: Stroma, Outer Invasive, Inner Invasive, and Tumor Core. Number of cells per mm&lt;sup&gt;2&lt;/sup&gt; and VCAN percentage were counted in these regions. &lt;b&gt;B,&lt;/b&gt; Box plot showing desert tissues under the lower quartile. &lt;b&gt;C,&lt;/b&gt; Comparison of cells in the stromal zone and epithelial zone to determine excluded and inflamed tissues. Line indicates a ratio of 0.75. &lt;b&gt;D,&lt;/b&gt; Pie charts showing distribution of phenotypes for 26 tissues. Table showing phenotype per tissue for CD8&lt;sup&gt;+&lt;/sup&gt; T cells and CD68&lt;sup&gt;+&lt;/sup&gt; macrophages. &lt;b&gt;E,&lt;/b&gt; Pie charts showing phenotypes within each tissue. Graphs comparing levels of CD8&lt;sup&gt;+&lt;/sup&gt; T cells in the epithelial zone (EZ) and stromal zone (SZ).&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Data from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;div&gt;Abstract&lt;p&gt;Immunotherapies for cancers of epithelial origin have limited efficacy, and a growing body of evidence links the composition of extracellular matrix (ECM) with the likelihood of a favorable response to treatment. The ECM may be considered an immunologic barrier, restricting the localization of cytotoxic immune cells to stromal areas and inhibiting their contact with tumor cells. Identifying ECM components of this immunologic barrier could provide targets that whether degraded &lt;i&gt;in situ&lt;/i&gt; may support antitumor immunity and improve immunotherapy response. Using a library of primary triple-negative breast cancer tissues, we correlated CD8&lt;sup&gt;+&lt;/sup&gt; T-cell tumor contact with ECM composition and identified a proteoglycan, versican (VCAN), as a putative member of the immunologic barrier. Our analysis reveals that CD8&lt;sup&gt;+&lt;/sup&gt; T-cell contact with tumor associates with the location of VCAN expression, the specific glycovariant of VCAN [defined through the pattern of posttranslational attachments of glycosaminoglycans (GAG)], and the cell types that produce the variant. In functional studies, the isomers of chondroitin sulfate presented on VCAN have opposing roles being either supportive or inhibiting of T-cell trafficking, and removal of the GAGs ameliorates these effects on T-cell trafficking. Overall, we conclude that VCAN can either support or inhibit T-cell trafficking within the tumor microenvironment depending on the pattern of GAGs present, and that VCAN is a major component of the ECM immunologic barrier that defines the type of response to immunotherapy.&lt;/p&gt;Significance:&lt;p&gt;The response to immunotherapy has been poor toward solid tumors despite immune cells infiltrating into the tumor. The ECM has been associated with impacting T-cell infiltration toward the tumor and in this article we have

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, TABLE 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Antibodies for IHC. Optimized parameters for each antibody&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 2 shows CS analysis from FFPE tissue sections&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;VCAN expression in different phenotypes and areas. IHC staining for VCAN completed on 26 tissues. Phenotypes for tissues based on CD8&lt;sup&gt;+&lt;/sup&gt; T-cell analysis. Images analyzed for VCAN percentage in whole area (&lt;b&gt;A&lt;/b&gt;), each region (&lt;b&gt;B&lt;/b&gt;), in areas split by phenotype (&lt;b&gt;C&lt;/b&gt;) and in each phenotype split by zone (&lt;b&gt;D&lt;/b&gt;). One-way ANOVA. &lt;b&gt;E,&lt;/b&gt; Percentage of CD8&lt;sup&gt;+&lt;/sup&gt; T cells compared with percentage of VCAN in each zone. Phenotypes indicated by color of dot. Spearman rank correlation. &lt;b&gt;F,&lt;/b&gt; Number of VCAN&lt;sup&gt;+&lt;/sup&gt; cells determined from RNAscope. Comparison between phenotypes in all areas and in specific zones. &lt;b&gt;G,&lt;/b&gt; Versikine levels determined from IHC staining on 30 tissues. Comparison between phenotypes in all areas and in specific zones. &lt;b&gt;H,&lt;/b&gt; VCAN stained on a consecutive slide. Comparison of VCAN and versikine in the different zones. Spearman rank correlation completed for each phenotype. *, &lt;i&gt;P&lt;/i&gt; &lt; 0.05; **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 7 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Effect of CS toward T-cell invasion. &lt;b&gt;A,&lt;/b&gt; CS MS completed on the crude and enriched protein from HMF3S and HCC38 cell lines. CS isomers and A/C ratio determined. &lt;b&gt;B,&lt;/b&gt; Transwell assay completed with 5 µg of each protein sample. Each sample was treated with ChABC for comparison. Heat map shows level of T cells invaded over time for one T-cell donor. Graphs show the level of migrated cells for HMF3S (&lt;b&gt;C&lt;/b&gt;) and HCC38 (&lt;b&gt;D&lt;/b&gt;) with error bars showing replicates with different T-cell donors.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 5 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;VCAN, CS, and CS-proteoglycans in different phenotypes. IHC completed for VCAN and CS on consecutive sections of 26 TNBC tissues. &lt;b&gt;A,&lt;/b&gt; Spread of CS levels across regions in excluded and inflamed tissues. Tissues were analyzed by IHC using the CS56 antibody which can detect both A and C isomers of CS. &lt;b&gt;B,&lt;/b&gt; CS and VCAN percentage determined from the same areas of consecutive slides. Correlations determined for stains in each region of excluded and inflamed tissues. Spearman rank correlation. &lt;b&gt;C,&lt;/b&gt; IHC staining completed for BGN and DCN on 30 TNBC tissues. Percentage of stains compared between phenotypes and regions. RM one-way ANOVA. *, &lt;i&gt;P&lt;/i&gt; &lt; 0.05; **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01; ***, &lt;i&gt;P&lt;/i&gt; &lt; 0.005; ****, &lt;i&gt;P&lt;/i&gt; &lt; 0.001.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 2 shows CS analysis from FFPE tissue sections&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, TABLE 2 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Primers for qRT-PCR. Primer sequences for VCAN isoforms and housekeeping gene RPS13&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 3 describes the transwell model&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 4 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Expression of VCAN in tissues and cells. &lt;b&gt;A,&lt;/b&gt; VCAN protein expression from IHC compared with gene expression from RNAscope. Spearman rank correlation. &lt;b&gt;B,&lt;/b&gt; Comparison of FAP&lt;sup&gt;+&lt;/sup&gt; cells and percentage of α-SMA staining with number of VCAN&lt;sup&gt;+&lt;/sup&gt; cells. Each dot is colored to represent TIP. Red = inflamed, Gray = excluded, Blue = desert. &lt;b&gt;C,&lt;/b&gt; Structure of VCAN isoforms and the number of predicted CS chains attached. qRT-PCR for VCAN isoforms completed on RNA extracted from frozen TNBC tissues (&lt;i&gt;N&lt;/i&gt; = 9; &lt;b&gt;D&lt;/b&gt;), fibroblasts (&lt;b&gt;E&lt;/b&gt;), primary fibroblasts from healthy patients (&lt;i&gt;N&lt;/i&gt; = 2) and from paired tumor and surround areas of patients with TNBC (&lt;i&gt;N&lt;/i&gt; = 4), immortalized mammary fibroblast cell line (HMF3S; &lt;i&gt;N&lt;/i&gt; = 4; TNBC cell lines HCC38 and MDAMB468 (&lt;i&gt;N&lt;/i&gt; = 4; &lt;b&gt;F&lt;/b&gt;). Coculture of HMF3S with HCC38 and MDAMB468 at a 4:1 ratio (&lt;i&gt;N&lt;/i&gt; = 4; &lt;b&gt;G&lt;/b&gt;). CT values for each gene normalized to CT values for housekeeping gene RPS13 to form ΔCT. **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;CS isomers expression in tissues. &lt;b&gt;A,&lt;/b&gt; Structure of CS isoforms following digestion of the chains with ChABC. CS extracted from FFPE tissues in the epithelial zone and stromal zone. CS isoforms analyzed by MS to identify proportion of each isomer. &lt;b&gt;B,&lt;/b&gt; Comparison of isoforms in excluded and inflamed tissues within the different zones. Two-way ANOVA. &lt;b&gt;C,&lt;/b&gt; Comparison of isomer in the different zones within excluded and inflamed tissues. Two-way ANOVA. &lt;b&gt;D,&lt;/b&gt; CS-A/C ratio determined for the different regions of each phenotype and compared. ANOVA. &lt;b&gt;E,&lt;/b&gt; Level of sulfation per CS disaccharide in the different regions of each phenotype compared. *, &lt;i&gt;P&lt;/i&gt; &lt; 0.05; **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01; ****, &lt;i&gt;P&lt;/i&gt; &lt; 0.001.&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 6 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 6 shows VCAN analysis in the TIPs from the second tissue subset&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, Supplementary Figure 1 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;Supplementary Figure 1 shows how VCAN was enriched and mass spectrometry analysis of the sample&lt;/p&gt;</jats:p>

Other

Hirani P, McDermott J, Rajeeve V, Cutillas PR, Jones JL, Pennington DJ, Wight TN, Santamaria S, Alonge KM, Pearce OMTet al., 2024, FIGURE 3 from Versican Associates with Tumor Immune Phenotype and Limits T-cell Trafficking via Chondroitin Sulfate

<jats:p>&lt;p&gt;VCAN expression in different phenotypes and areas. IHC staining for VCAN completed on 26 tissues. Phenotypes for tissues based on CD8&lt;sup&gt;+&lt;/sup&gt; T-cell analysis. Images analyzed for VCAN percentage in whole area (&lt;b&gt;A&lt;/b&gt;), each region (&lt;b&gt;B&lt;/b&gt;), in areas split by phenotype (&lt;b&gt;C&lt;/b&gt;) and in each phenotype split by zone (&lt;b&gt;D&lt;/b&gt;). One-way ANOVA. &lt;b&gt;E,&lt;/b&gt; Percentage of CD8&lt;sup&gt;+&lt;/sup&gt; T cells compared with percentage of VCAN in each zone. Phenotypes indicated by color of dot. Spearman rank correlation. &lt;b&gt;F,&lt;/b&gt; Number of VCAN&lt;sup&gt;+&lt;/sup&gt; cells determined from RNAscope. Comparison between phenotypes in all areas and in specific zones. &lt;b&gt;G,&lt;/b&gt; Versikine levels determined from IHC staining on 30 tissues. Comparison between phenotypes in all areas and in specific zones. &lt;b&gt;H,&lt;/b&gt; VCAN stained on a consecutive slide. Comparison of VCAN and versikine in the different zones. Spearman rank correlation completed for each phenotype. *, &lt;i&gt;P&lt;/i&gt; &lt; 0.05; **, &lt;i&gt;P&lt;/i&gt; &lt; 0.01.&lt;/p&gt;</jats:p>

Other

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00622776&limit=30&person=true